701 related articles for article (PubMed ID: 25770404)
41. Monitoring of unfractionated heparin using activated partial thromboplastin time: an assessment of the current nomogram and analysis according to age.
Kim JS; Lee HJ; Sung JD; Kim HJ; Lee SY; Kim JS
Clin Appl Thromb Hemost; 2014 Oct; 20(7):723-8. PubMed ID: 23615295
[TBL] [Abstract][Full Text] [Related]
42. Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics.
Trucco M; Lehmann CU; Mollenkopf N; Streiff MB; Takemoto CM
J Thromb Haemost; 2015 May; 13(5):788-94. PubMed ID: 25740425
[TBL] [Abstract][Full Text] [Related]
43. Pseudo Heparin Resistance After Pulmonary Endarterectomy: Role of Thrombus Production of Factor VIII.
Nykänen AI; Selby R; McRae KM; Zhao Y; Asghar UM; Donahoe L; Granton J; de Perrot M
Semin Thorac Cardiovasc Surg; 2022; 34(1):315-323. PubMed ID: 33984481
[TBL] [Abstract][Full Text] [Related]
44. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device.
Stulak JM; Lee D; Haft JW; Romano MA; Cowger JA; Park SJ; Aaronson KD; Pagani FD
J Heart Lung Transplant; 2014 Jan; 33(1):60-4. PubMed ID: 24021944
[TBL] [Abstract][Full Text] [Related]
45. Should we abandon the APTT for monitoring unfractionated heparin?
Arachchillage DRJ; Kamani F; Deplano S; Banya W; Laffan M
Thromb Res; 2017 Sep; 157():157-161. PubMed ID: 28759760
[TBL] [Abstract][Full Text] [Related]
46. Artificial circulatory support with textured interior surfaces. A counterintuitive approach to minimizing thromboembolism.
Rose EA; Levin HR; Oz MC; Frazier OH; Macmanus Q; Burton NA; Lefrak EA
Circulation; 1994 Nov; 90(5 Pt 2):II87-91. PubMed ID: 7955291
[TBL] [Abstract][Full Text] [Related]
47. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
Kuhle S; Eulmesekian P; Kavanagh B; Massicotte P; Vegh P; Lau A; Mitchell LG
Haematologica; 2007 Apr; 92(4):554-7. PubMed ID: 17488668
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of weight-based dosing of unfractionated heparin in obese children.
Taylor BN; Bork SJ; Kim S; Moffett BS; Yee DL
J Pediatr; 2013 Jul; 163(1):150-3. PubMed ID: 23414664
[TBL] [Abstract][Full Text] [Related]
49. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
Baker BA; Adelman MD; Smith PA; Osborn JC
Arch Intern Med; 1997 Nov; 157(21):2475-9. PubMed ID: 9385299
[TBL] [Abstract][Full Text] [Related]
50. Gold standard in anticoagulation assessment of left ventricular assist device patients?: how about bronze.
Stehlik J; Johnson SA; Selzman CH
JACC Heart Fail; 2015 Apr; 3(4):323-6. PubMed ID: 25770402
[No Abstract] [Full Text] [Related]
51. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
[TBL] [Abstract][Full Text] [Related]
52. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
[TBL] [Abstract][Full Text] [Related]
53. Monitoring heparin anticoagulation in the acute phase response.
Uprichard J; Manning RA; Laffan MA
Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
[TBL] [Abstract][Full Text] [Related]
54. Activated Partial Thromboplastin Time Versus Anti-Factor Xa Monitoring of Heparin Anticoagulation in Adult Venoarterial Extracorporeal Membrane Oxygenation Patients.
Kulig CE; Schomer KJ; Black HB; Dager WE
ASAIO J; 2021 Apr; 67(4):411-415. PubMed ID: 33769995
[TBL] [Abstract][Full Text] [Related]
55. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
[TBL] [Abstract][Full Text] [Related]
56. Monitoring unfractionated heparin in pediatric patients with congenital heart disease having cardiac catheterization or cardiac surgery.
Kim GG; El Rouby S; Thompson J; Gupta A; Williams J; Jobes DR
J Thromb Thrombolysis; 2010 May; 29(4):429-36. PubMed ID: 19714446
[TBL] [Abstract][Full Text] [Related]
57. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
58. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
59. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation.
Toulon P; Smahi M; De Pooter N
J Thromb Haemost; 2021 Aug; 19(8):2002-2006. PubMed ID: 33555096
[TBL] [Abstract][Full Text] [Related]
60. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
